Lv1
10 积分 2025-03-12 加入
Improved event-free survival after complete or major pathologic response in patients with resectable NSCLC treated with neoadjuvant chemoimmunotherapy regardless of adjuvant treatment: a systematic review and individual patient data meta-analysis
1天前
已完结
CTLA-4 Control over Foxp3 + Regulatory T Cell Function
2个月前
已完结
Regulatory T cells converted from Th1 cells in tumors suppress cancer immunity via CD39
2个月前
已完结
Timing of nivolumab with neoadjuvant carboplatin and paclitaxel for early triple-negative breast cancer (BCT1902/IBCSG 61–20; Neo-N): a non-comparative, open-label, randomised, phase 2 trial
2个月前
已完结
皖公网安备34019202002308
